Evidence map›Paper›PMID 36370068›Full record

ArticleAnnals of medicine2022

Recent trends in the incidence and survival of stage I liver cancer: a surveillance, epidemiology, and end results analysis.

Xue-Chen Yu, Ji-Bin Liu, Qing-Hai Tang, Xun Diao, Qi-Yu Fan, Zhong-Yan Huang, Xiao-Mei Tang, Sha Li, Yong-Feng Cao, Yu-Shui Ma and 1 more

Open access · goldAbstract read
In one paragraph

Article in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. RNA m6A methylation regulators in liver cancer.Cancer cell international · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Xue-Chen YuInstitute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China.
Ji-Bin LiuInstitute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China.
Qing-Hai TangHunan Key Laboratory for Conservation and Utilization of Biological Resources in the Nanyue Mountainous Region and College of Life Sciences and Environment, Hengyang Normal University, Hengyang, China.
Xun DiaoInstitute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China.
Qi-Yu FanInstitute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China.
Zhong-Yan HuangGeneral Surgery, Ruijin Hospital & Institute of Pancreatic Diseases, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xiao-Mei TangGeneral Surgery, Ruijin Hospital & Institute of Pancreatic Diseases, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Sha LiInstitute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China.
Yong-Feng CaoDepartment of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China.
Yu-Shui MaCancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Da FuGeneral Surgery, Ruijin Hospital & Institute of Pancreatic Diseases, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Nantong University · CNRuijin Hospital · CNHengyang Normal University · CNLonghua Hospital Shanghai University of Traditional Chinese Medicine · CNMacalester College · USNantong Tumor Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImprovements in screening and imaging technologies and treatment of liver disease have influenced the trend in diagnosis for stage I liver cancer. In this article, recent trends in age, incidence, tumour size, and survival of different stages of liver cancer are analysed.

methodsSurveillance, Epidemiology, and end results data from the National Cancer Institute were used to analyse trends in age-adjusted incidence rate, mean tumour size at diagnosis, age at diagnosis, and 5-year survival probability for stage I liver cancer.

resultsStage I cases of liver cancer increased most tremendously over the study period, with a greater increase from 2004 to 2012 following a smaller increase from 2012 to 2015. Moreover, the mean age of stage I liver cancer increased by 1.72 years from 2004 to 2015. The 5-year-overall survival for stage I liver cases worsened from 97.9% to 83.7% from 2004 to 2011, whereas the 10-year survival probability for stage I cases worsened from 97.3% in 2004 to 79.6% in 2006. Comparing with higher stage cases, stage I liver cancer were more likely to be females, be married, live in metro areas, receive chemotherapy, and carry medical insurance.

conclusionsThe incidence of stage I liver cancer has increased over the study period, with an increase in age of diagnosis, decrease in tumour size, and generally stable overall survival rate with slight decrease. These trends emphasized the importance of early detection of liver cancer and regular screening and better treatment for high-risk populations.RESEARCH HIGHLIGHTSImprovements in screening and imaging technologies and treatment of liver disease have influenced the trend in diagnosis for liver cancer.Stage I cases of liver cancer increased most tremendously over the study period, with a greater increase from 2004 to 2012 following a smaller increase from 2012 to 2015.These trends emphasized the importance of early detection of liver cancer and regular screening and better treatment for high-risk populations.

Indexed as

Liver NeoplasmsMass ScreeningFemaleHumansIncidenceInfantMaleSEER ProgramSurvival RateUnited StatesHCCprognosisSEERstagetreatment

Identifiers

PMID36370068
PMCPMC9662040
OpenAlexW4308825542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.